Over the last 7 days, the United States market has dropped 2.5%, but it remains up 23% over the past year with earnings forecasted to grow by 17% annually. For investors looking beyond well-known stocks, penny stocks—often representing smaller or newer companies—can present intriguing opportunities despite their somewhat outdated label. By focusing on those with strong financial health and potential for growth, investors might uncover valuable options in this niche area of the market.

Below we spotlight a couple of our favorites from our exclusive screener.

ProQR Therapeutics (PRQR)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to discovering and developing novel therapeutic medicines, with a market cap of $158.04 million.

Operations: The company's revenue is primarily generated from the discovery and development of innovative RNA-based therapeutics, amounting to €13.64 million.

Market Cap: $158.04M

ProQR Therapeutics, a clinical-stage biotechnology firm, is navigating the challenges of being pre-revenue with sales of €2.03 million in Q1 2026, down from €4.52 million a year prior. Despite its unprofitability and negative return on equity, ProQR has reduced its debt significantly over five years and maintains more cash than total debt. The company’s short-term assets exceed both long-term and short-term liabilities, providing financial stability. Recent board changes and an increase in authorized capital aim to bolster growth opportunities as ProQR continues developing RNA-based therapeutics while managing shareholder dilution effectively over the past year.

Blue Ridge Bankshares (BRBS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Blue Ridge Bankshares, Inc. is a bank holding company for Blue Ridge Bank, National Association, offering commercial and consumer banking and financial services with a market cap of $293.82 million.

Operations: The company generates revenue of $93.49 million from its operations in the United States.

Market Cap: $293.82M

Blue Ridge Bankshares has recently turned profitable, marking a significant shift in its financial performance. The company's net income for Q1 2026 was US$0.836 million, a turnaround from the previous year's loss. Its revenue of US$93.49 million indicates stable operations, supported by an appropriate loans to assets ratio of 75% and primarily low-risk funding sources like customer deposits. Despite recent executive changes, including the appointment of Harry Golliday as interim CEO, Blue Ridge maintains high-quality earnings and stable weekly volatility at 6%. However, its return on equity remains low at 4.3%, reflecting potential areas for improvement in profitability metrics moving forward.

Myomo (MYO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Myomo, Inc. is a wearable medical robotics company that designs, develops, and produces myoelectric orthotics for individuals with neuromuscular disorders across the United States, Germany, and other international markets; it has a market cap of $49.46 million.

Operations: The company generates revenue primarily from its Medical Products segment, amounting to $41.21 million.

Market Cap: $49.46M

Myomo, Inc., a wearable medical robotics company, faces challenges with its unprofitable status and negative return on equity. Despite these hurdles, it has shown revenue growth potential, with sales reaching US$10.11 million in Q1 2026 and projected annual revenue between US$43 million to US$46 million. The company's seasoned management team and board provide stability amid high volatility in share price. Recent partnerships, such as expanded access through Ottobock Care clinics and agreements with Elevance Health plans covering over 80 million lives, aim to broaden product reach. Myomo's cash position currently exceeds its total debt but remains limited by less than a year of cash runway under current conditions.

Key Takeaways

• Gain an insight into the universe of 335 US Penny Stocks by clicking here.
• Looking For Alternative Opportunities? Trump's oil boom is here — pipelines are primed to profit. Discover the 23 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.